Researcher at the University of Toronto in Canada and University of São Paulo in Brazil have developed a method of getting rid of bacteria and viruses from donor organs using…
A company developing gene therapies for neurodegenerative diseases has closed a round of financing that it hopes will bring it into clinical development.
DeviceTalks is proud to announce that it has partnered with MassMEDIC for the second year to bring the MassMEDIC MedTech Showcase to DeviceTalks Boston on June 5-6 at the Seaport World Trade Center.
Cambridge-based engineering biology company Sherlock Biosciences this week announced its launch with $35 million in financing — and its eyes are on CRISPR gene-editing tech.
Researchers from Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center and Dana-Farber Cancer Institute have joined forces with DNA sequencing giant Illumina and its liquid-biopsy spinoff Grail to develop a new assay.
Microsoft aims to bring its coding skills to bear on biotech, with the goal of building an end-to-end platform for programming the biology of living cells to better produce new medicines and potentially materials that could be applicable to a range of industries.
Silicon Valley DNA testing company 23andMe has announced a new test meant to identify genetic risk for Type 2 diabetes, expanding its health products to one of the country’s most widespread chronic conditions.
Long before memory loss occurs in patients with Alzheimer’s, the protein amyloid-beta—which has been implicated in the formation of brain tangles that characterize the disease—starts building up in the spinal fluid. Problem is, detecting the protein there requires an invasive procedure that’s done under anesthesia, making it impossible to deploy on a widespread basis for the early detection of Alzheimer’s.